Press
-
IntelliDose Launches IntelliScribe
March 2, 2010
-
IntrinsiQ Sharpens Cancer Treatment Analysis
February 10, 2010
-
Dayton Physicians Commits to Clinical Excellence by Partnering with IntelliDose
February 2, 2010
-
IntelliDose Exhibiting at Fifth Annual Community Oncology Conference
February 5–6, 2010
-
New York cancer care center uses automation to handle coding, reimbursement
January 29, 2010
-
Tarceva Reprieve? FDA Delay Could Mean Little Either Way
January 25, 2010
-
WWMR Vice President Invited to Speak at PBIRG Fall Biotech Workshop
December 7, 2009
-
Panel Advises on Clinical Pathways: What, Why, and How
November, 2009
-
IntrinsiQ Expands Executive Team
November 3, 2009
-
IntelliDose Exhibiting at North Carolina Oncology Management Society 2009 Fall Conference
November 18 to 20, 2009
-
Opportunity reconsidered: maintenance therapy in oncology
October, 2009
-
IntrinsiQ Study: Oncologists Overlook Maintenance Therapy Option – More Often than They Realize
September 15, 2009
-
Industry Thought Leaders: A Discussion with Jeff Forringer, President of IntrinsiQ, LLC
August 2009
-
Are CPOEs worth the investment?
August 2009
-
Information Technology: Tracking the Evolution of Oncology Drug Prescribing
August 2009
-
Rich Gray, General Manager of IntelliDose, to Speak at ACCC 26th National Oncology Economics Conference
September 22 to 25, 2009
-
IntelliDose Exhibiting at eClinicalWorks 2009 National Users Conference
September 12 to 15, 2009
-
Jeff Forringer, President of IntrinsiQ, to Speak at the Magellan/ICORE 6th Annual Oncology Summit
September 11, 2009
-
IntelliDose Exhibiting at GE Centricity User Group Fall Conference
August 28 and 29, 2009
-
How Much Should Cancer Drugs Cost: Landmark Cornell University Study Sheds New Light on Old Assumptions
August 4, 2009
-
IntrinsiQ Sponsors Cancer Center Business Summit
October 8-9, 2009
-
The First Step to a Paperless Practice
July 1, 2009
-
On the Move – Spotlight on Jeff Forringer
June 19, 2009
-
Specialized chemotherapies increase market share, cost of care
June 2009
-
IntrinsiQ Acquires Market Research Firm WWMR
June 9, 2009
-
IntrinsiQ Appoints New Executive Team
May 12, 2009
-
IntrinsiQ's IntelliDose
May 2009
-
The real cost of treating off-label and off-guidelines
March 2009
-
NewsMakers
March 2009
-
Small mistakes, huge consequences; Onc-specific software improves safety
February 2009
-
Safe Handling; The Right Drug, Right Dose, Right Patient
January/February 2009
-
Automated Oncology
February 2009
-
Still Using Paper and Pen?
January 2009
-
OnCare Hawaii Selects IntelliDose for Oncology Patient Safety and Practice Efficiency
January 6, 2009
-
Safe Handling
December 2008
-
Market Opportunity in Lung Cancer
December 2008
-
Cancer Center of South Florida Selects IntelliDose for All-Electronic Practice
November 3, 2008
-
IntrinsiQ Launches IntelliDose 3.8
October 27, 2008
-
Technology: Can Oncology EMRs Improve Quality?
September 2008
-
IntrinsiQ Builds Out Its Oncology-Products Market Analytics
September 2008
-
IntrinsiQ Wins 3 Top Honors from Inc. Magazine
September 9, 2008
-
New Reporting from IntrinsiQ Measures Impact of Key Events on Oncology Drug Usage
September 2, 2008
-
High Drug Costs a Factor in Cancer Care
August 28, 2008
-
Pharmawire analysis: Cyclacel's seliciclib comes under physician scrutiny
August 2008
-
DSS Licenses IntelliDose to Standardize VA Oncology Practices
August 18, 2008
-
Buried Treasure
June 23, 2008
-
Data from the Doctor
April 15, 2008
-
IntrinsiQ LLC - Dose of Success
March 7, 2008
-
IntelliCost Provides Cost of Therapy Insight for Sizing New Market Opportunities
February 13, 2008
-
Software application aims to eliminate human error in chemotherapy dosing
January 11, 2008
-
Oncologists Nationwide Choose IntelliDose for Clinical Safety and Efficiency
November 28, 2007
-
IntrinsiQ Expands Oncologys Gold-Standard for Patient Data Collection
September 25, 2007
-
IntelliDose to Participate in ASCO EHR Symposium
July 19, 2007
-
GE Healthcare and IntrinsiQ Announce Collaboration to Link Clinical Oncology Information within Patient Electronic Medical Records
May 31, 2007
-
IntelliDose® Unveils IntelliCharge — Automated Encounter Charge Capture Improves Control and Billing of Costly Chemotherapy Drugs
May 31, 2007
-
PRA International and IntrinsiQ Research Enter Exclusive Agreement for Oncology Patient Treatment Data
March 19, 2007
-
Pulse and IntrinsiQ Sign Strategic Agreement
January 16, 2007
-
IMS, IntrinsiQ Research Establish Strategic Alliance to Deliver Global, Clinically Rich Oncology Market Intelligence
August 2, 2006
-
Accel-KKR Acquires Majority Stake in IntrinsiQ
June 20, 2006
Small mistakes, huge consequences; Onc-specific software improves safety
By Ron Piana
February 24, 2009
Source: CancerNetwork
BOSTON--In 1994, Betsy Lehman—a 39-year-old health columnist for the Boston Globe—was undergoing breast cancer treatment at Dana-Farber Cancer Institute. A doctor at the center read the handwritten chemotherapy order as 4 g/m2 per day, instead of 4 g/m2 spread over 4 days. Consequently, she received four times the intended dose for 4 consecutive days—a fatal overdose. Betsy Lehman’s death by medical error sent shockwaves throughout Dana-Farber, prompting, among other changes, adoption of an electronic chemotherapy order-entry system that red-flag’s discrepancies in chemo dosage.
Small market, idiosyncratic language
Although Dana-Farber and other IT-engaged institutions report a marked increase in efficiencies and safety outcomes, adoption of health IT by community oncologists remains sluggish. It’s not just tech-shy docs worried about start-up costs and office disruption. Major health IT players have also been slow to develop products for oncologists; the market is relatively small, and the language and workflow is more challenging to manage than most sub-specialties.
Fortunately, some vendors are developing systems that might persuade the oncology community to abandon error-prone paper-based calculations, such as IntelliDose, created by the Boston-based company, IntrinsiQ directly after the Dana-Farber tragedy. According to product manager, Andrew Scott, “IntelliDose is an oncology-specific software application that completely automates the order-entry, administration, and documentation process of delivering chemotherapy to cancer patients.”
Although IntelliDose is not a complete EMR, Mr. Scott pointed out “that 80% of the work a community oncologist does is about managing chemotherapy regimens. IntelliDose manages all of the daily workflow issues on one piece of software.” He said that the software creates efficiencies by relieving the burden placed on pharmacy and infusion nurses for double-checking calculations and interpreting handwriting.
A good place to start
One concern about adopting health IT in a stepwise process is modularity. According to Mr. Scott, IntelliDose has very tight interface and integration capabilities. “Once an office is up and running with IntelliDose and they make a move to a large EMR system, we basically just have to hook the applications together. We have a comprehensive set of inbound interfaces that simplifies the process,” said Mr. Scott.
IntelliDose can also be interfaced with hospital EMRs, labs, and pharmacies. Mr. Scott explained that the system verifies lab results, calculates drug doses, supports nurse charting, and allows physicians to write take-home prescriptions. “It also offers a charge capture feature and pulls demographic data from hospital- and office-based administrative systems,” added Mr. Scott.
Mr. Scott said that integrating IntelliDose into a practice is a one-step process that can be maximized by “using voice-activated transcription. And if the workflow involves mobile use, IntelliDose is flexible enough to operate on a laptop, tablet PC or desktop PC at a small one or two doctor practice or a large cancer network.”
But Mr. Scott emphasized that although IntelliDose increases office efficiencies, patient safety is paramount. “IntelliDose,” said Mr. Scott, “improves patient safety not only by automating the ordering process, but providing a central repository for tracking medications that have been administered to each patient.”